5 Results for "

DFO

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "DFO" in MCE Product Catalog:

454
454 Cited Publications
Cat. No.: HY-B0988
CAS No.: 138-14-7
Synonyms: Desferrioxamine B mesylate; DFOM
Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19 .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-D0903
CAS No.: 54078-29-4
Synonyms: DFO
1,8-Diazafluoren-9-one (DFO) is a chemical that is used to find fingerprints on porous surfaces. 1,8-Diazafluoren-9-one reacts with amino acids present in the fingerprint to form highly fluorescent derivatives (Ex/Em = ~470/570).
loading...
    loading...
Cat. No.: HY-158067
CAS No.: 2359695-48-8
Purity:  89.40%
Synonyms: DFO-DBCO
Deferoxamine-DBCO (DFO-DBCO) is a bifunctional small-molecule synthetic building block obtained by covalent conjugation of the DFO metal-chelating group with DBCO, and is a bifunctional chelator. Deferoxamine-DBCO efficiently chelates radioactive metals (such as 89Zr) through the DFO moiety to achieve radiolabeling. Deferoxamine-DBCO undergoes a metal-free Huisgen cycloaddition reaction with azide-containing biomolecules (such as siRNA and monoclonal antibodies) through the DBCO moiety under bioorthogonal conditions to accomplish targeted conjugation. Deferoxamine-DBCO is applicable to research related to bioconjugation chemistry and the preparation of PET radiotracer probes .
loading...
    loading...
Cat. No.: HY-170749
CAS No.: 2910882-32-3
Target:  

Drug Intermediate

Research Areas:  

Others

DFO-BCN is a drug intermediate, that can be used for synthesis of PET/CT imaging agent DFO-CPC634 through click chemistry .
loading...
    loading...
Cat. No.: HY-P992341

Target:  

MMP

Research Areas:  

Cancer

D8P1C1 is a high-affinity ADAM17 inhibitor (with a Kd of 180 pM targeting ADAM17-ECD) that reduces the shedding and phosphorylation of EGFR ligands. D8P1C1 inhibits cancer cell proliferation in vitro and tumor growth in xenograft models. 89Zr-DFO-D8P1C1 radioimmunological PET imaging shows its substantial accumulation in ovarian tumor xenografts, serving as a platform for generating bispecific T-cell engager derivatives. D8P1C1 can be applied to research on related diseases including triple-negative breast cancer, various types of ovarian cancer, lung adenocarcinoma, glioma, and colon cancer .
loading...
    loading...